
WO 03/062826

PCT/GB03/00329


Figure 1



WO 03/062826

PCT/GB03/00329

Figure 2




H-19 .



WQ 03/062826

PCT/GB03/00329

Figure 3




.9/502470

WO 03/062826

PCT/GB03/00329

Figure 4




10/502/20

PCT/GB03/00329

WO 03/062826

Figure 5



PCT/GB03/00329

WO 03/062826

Figure 6

CNE-2

HX1

H19

IGF-2



 β -actin







WO 03/062826

PCT/GB03/00329

Figure 7



	Position of CpG sites No. of closus sequenced	-209	-189	-180	-139	-117	-102	-92	-68	-54	-41	-15	4
CNE-2	19	1 (5%)	1 (5%)	1 (5%)	0	٥	0	0	0	0	0	0	0
HK1	63	50 (79%)	47 (75%)	45 (71%)	13 (21%)	45 (71%)	49 (78%)	2(3%)	2 (3%)	5 (8%)	6 (10%)	5 (8%)	0
HK1(+AzC)	27	6 (22%)	5 (19%)	6 (22%)	4 (15%)	10 (27%)	8 (30%)	0	0	0	٠.	1 (4%)	0
		Number of methylated clones											



WO 03/062826

PCT/GB03/00329

Figure 8

